孕激素受体状态与乳腺癌预后的关联:一个元分析
Yiming Hou1, Jianrong Li1, Qiong Zhang1
1Third Affiliated Hospital of Beijing University of Chinese Medicine, Beijing University of Chinese Medicine, Beijing, 100105, China.
World journal of surgical oncology
|October 2, 2025
概括
乳腺癌 (BC) 中的孕激素受体 (PR) 消极性与较差的生存结果有关. 这一发现在各种生存指标和患者子组中是一致的,突出显示PR状态是关键的预后因素.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 临床研究 临床研究
背景情况:
- 乳腺癌 (BC) 的预后受到激素受体状态的影响,而孕激素受体 (PR) 状态具有有争议的影响.
- 临床特征可能会影响PR状态在BC预后中的有争议作用.
研究的目的:
- 为了确定孕激素受体 (PR) 状态对乳腺癌 (BC) 预后的影响.
- 探索不同患者亚组中PR状态影响的变化.
主要方法:
- 在PubMed,Cochrane图书馆,Embase和Web of Science的系统文献搜索,直到2024年7月.
- 使用纽卡斯尔-太华尺度 (NOS) 进行包含研究的质量评估.
- 使用STATA 15.1.1.进行的元分析.
主要成果:
- 包括35项涉及89,164名患者的研究.
- PR阴性状态与较差的整体存活率 (HR 1.70),无病存活率 (HR 1.62),乳腺癌特异性存活率 (HR 2.45) 和无复发性存活率 (HR 1.47) 显著相关.
- 亚组分析表明,区域,雌激素受体 (ER) 状态,人体表皮生长因子受体2 (HER2) 状态,更年期状态和转移状态影响了结论.
结论:
- 孕激素受体 (PR) 表达的丧失与乳腺癌 (BC) 的较差结果有关.
- PR状态的预后意义受各种临床特征的影响.
- PR状态可以作为额外的预测标志物,特别是在ER阳性,HER2阴性瘤患者中.
更多相关视频
07:41Performing Data Mining And Integrative Analysis Of Biomarker in Breast Cancer Using Multiple Publicly Accessible Databases
Published on: May 17, 2019
9.5K
09:08Integration of Bioinformatics Approaches and Experimental Validations to Understand the Role of Notch Signaling in Ovarian Cancer
Published on: January 12, 2020
7.2K
相关概念视频
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
407
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
407
Cancer Survival Analysis
648
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
648
mTOR Signaling and Cancer Progression
4.6K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
4.6K
